Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Robert F. Kennedy Jr.'s removal of all members of the CDC's Advisory Committee on Immunization Practices has raised concerns about the upcoming meeting later this month. Analysts fear that the committee may become more sympathetic to anti-vaccine viewpoints. In other news, Merck has received FDA approval for an RSV antibody, Gilead has paused five HIV trials but Lenacapavir remains safe, and the FDA has reinstated a previously disbanded generic drug policy panel. Gilead has expressed faith in its HIV combo therapy and pledged to work with regulators to resolve the hold on its trials. In vitro cell research is focused on discovering interventions to slow aging and prevent age-related diseases.Kennedy's vaccine campaign is seen as breeding more distrust, while Metsera's weight loss injection has shown positive results. Merck is moving forward with an oral PCSK9 inhibitor. Thank you for tuning in to Pharma and Biotech daily for the latest updates in the pharmaceutical and biotechnology industries.

Support the show